[go: up one dir, main page]

SV1997000037A - Inhibisor de matrices de metaloproteasas mediante compuestos sustituidos de fenalquilo, - Google Patents

Inhibisor de matrices de metaloproteasas mediante compuestos sustituidos de fenalquilo,

Info

Publication number
SV1997000037A
SV1997000037A SV1997000037A SV1997000037A SV1997000037A SV 1997000037 A SV1997000037 A SV 1997000037A SV 1997000037 A SV1997000037 A SV 1997000037A SV 1997000037 A SV1997000037 A SV 1997000037A SV 1997000037 A SV1997000037 A SV 1997000037A
Authority
SV
El Salvador
Prior art keywords
disorders
metaloprotease
diseases
alnoria
mmp
Prior art date
Application number
SV1997000037A
Other languages
English (en)
Inventor
Donald J Wolanin
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of SV1997000037A publication Critical patent/SV1997000037A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182Radicals derived from carboxylic acids
    • C07D295/192Radicals derived from carboxylic acids from aromatic carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C17/00Preparation of halogenated hydrocarbons
    • C07C17/093Preparation of halogenated hydrocarbons by replacement by halogens
    • C07C17/16Preparation of halogenated hydrocarbons by replacement by halogens of hydroxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/84Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C07C45/46Friedel-Crafts reactions
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/76Unsaturated compounds containing keto groups
    • C07C59/88Unsaturated compounds containing keto groups containing halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738Esters of keto-carboxylic acids or aldehydo-carboxylic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE RELACIONA CON COMPUESTOS DE INHIBIDORES DE LA METALOPROTEASA DE MATRIZ, COMPOSICIONES FARMACEUTICAS DE LOS MISMOS Y UN METODO DE TRATAMIENTO DE ENFERMEDADES MEDIANTE EL USO DE DICHOS COMPUESTOS DE LA PRESENTE INVENCION TIENE LA FROMULA GENERAL I, ESTOS COMPUESTOS SON UTILES PARA INHIBIR LAS METALOPROTEASA DE MATRIZ Y POR LO TANTO, PARA COMBATIR LOS TRASTORNOS DE LOS CUALES CONTRIBUYEN LAS MMP, TALES COMO LA OSTEOARTRITIS, LA ARTRITIS REUMATOIDEA, LA ARTRITIS SEPTICA, LAS ENFEREMEDADES PERIODONTALES, LAS ULCERAS DE CORNEA, LA PROTEINURIA, AL ENFERMEDAD DE NEURISMA AORTICA, LA EPIDERMOLISIS DISTROFICA, LOS TRASTORNOS QUE PRODUCEN RESPUESTAS INFLAMATORIAS, LAS OSTEOPENIAS EN LAS QUE MEDIA LA ACTIVIDAD DE MMP, LA ENFERMEDAD DE LA ATICULACION TEMPOROANDIBULAR, LAS ENFERMEDADES DESMIELIZANTES DEL SISTEMA NERVIOSO; LAS METASTASIS DE TUMORES O LA PERDIDA DEGENERATIVA DE CARTILAGOS A LA LESION ARTICULAR TRAUMATICA Y TROMBOSIS CORONARIA POR RUPTURA DE PLACA ATEROESCLEROTICA, ASIMISMO ESTE INVENTO PRESENTA COMPOSICIONES FARMACEUTICAS Y METODOS PARA TRATAR DICHOS TRASTORNOS.
SV1997000037A 1996-05-15 1997-05-12 Inhibisor de matrices de metaloproteasas mediante compuestos sustituidos de fenalquilo, SV1997000037A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64502696A 1996-05-15 1996-05-15

Publications (1)

Publication Number Publication Date
SV1997000037A true SV1997000037A (es) 1999-01-14

Family

ID=24587359

Family Applications (1)

Application Number Title Priority Date Filing Date
SV1997000037A SV1997000037A (es) 1996-05-15 1997-05-12 Inhibisor de matrices de metaloproteasas mediante compuestos sustituidos de fenalquilo,

Country Status (24)

Country Link
EP (1) EP0907632B1 (es)
JP (1) JP3305328B2 (es)
CN (1) CN1124255C (es)
AR (1) AR007100A1 (es)
AT (1) ATE229497T1 (es)
AU (1) AU727899B2 (es)
BR (1) BR9709084A (es)
CA (1) CA2253870C (es)
CO (1) CO5070565A1 (es)
DE (1) DE69717811T2 (es)
DK (1) DK0907632T3 (es)
ES (1) ES2188943T3 (es)
HN (1) HN1997000071A (es)
HR (1) HRP970243B1 (es)
ID (1) ID17424A (es)
PA (1) PA8429801A1 (es)
PE (1) PE66298A1 (es)
PT (1) PT907632E (es)
SV (1) SV1997000037A (es)
TN (1) TNSN97082A1 (es)
TW (1) TW363056B (es)
WO (1) WO1997043247A1 (es)
YU (1) YU18497A (es)
ZA (1) ZA974029B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288063B1 (en) * 1998-05-27 2001-09-11 Bayer Corporation Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
TR200101970T2 (tr) * 1998-12-30 2002-03-21 Bayer Aktiengesellschaft Solunum yollarì hastalìklarìnìn tedavisinde matriks metaloproteaz inhibit”rleri olarak ikameli 4-biarilbutirik ve 5-biarilpentanoik asit trevlerinin kullanìlmasì
EP1031349A1 (en) * 1999-02-25 2000-08-30 Bayer Aktiengesellschaft Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of cerebral diseases
US7141607B1 (en) 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
FR2901320B1 (fr) * 2006-05-17 2008-07-04 Univ Savoie Etablissement Publ Dispositif miniaturise apte a fonctionner comme moteur ou refroidisseur selon un cycle thermodynamique de stirling
CA2944617A1 (en) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft Chiral 2,5-disubstituted cyclopentanecarboxylic acid derivatives and use thereof
EP3126358A1 (de) 2014-04-03 2017-02-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituierte cyclopentancarbonsäuren zur behandlung von atemwegserkrankungen
EP3126339A1 (de) 2014-04-03 2017-02-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituierte cyclopentancarbonsäuren und ihre verwendung

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3784701A (en) * 1970-09-21 1974-01-08 American Cyanamid Co Compositions containing substituted benzoylpropionic acids and method of use to treat inflammation and pain
DE2112716A1 (de) * 1971-03-17 1972-10-05 Thomae Gmbh Dr K Neue 4-(4-Biphenylyl)-4-oxobuttersaeuren,ihre Salze und ihre Ester
US5789434A (en) * 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
CO5011071A1 (es) 1996-05-15 2001-02-28 Bayer Corp Inhibicion de las metaloproteinasas de matriz por acidos 2-(w/aroilalquil)-4-biaril-4-oxobutiricos y composiciones farmaceuticas que los contienen

Also Published As

Publication number Publication date
CA2253870C (en) 2004-01-06
PE66298A1 (es) 1998-10-23
PT907632E (pt) 2003-04-30
EP0907632A1 (en) 1999-04-14
CO5070565A1 (es) 2001-08-28
JPH11510517A (ja) 1999-09-14
CN1225624A (zh) 1999-08-11
ES2188943T3 (es) 2003-07-01
WO1997043247A1 (en) 1997-11-20
HRP970243B1 (en) 2002-06-30
DE69717811T2 (de) 2003-05-28
CA2253870A1 (en) 1997-11-20
JP3305328B2 (ja) 2002-07-22
ATE229497T1 (de) 2002-12-15
BR9709084A (pt) 1999-08-03
ID17424A (id) 1997-12-24
TW363056B (en) 1999-07-01
DK0907632T3 (da) 2003-04-07
HRP970243A2 (en) 1998-04-30
TNSN97082A1 (fr) 2005-03-15
YU18497A (en) 1999-11-22
HN1997000071A (es) 1997-06-18
DE69717811D1 (en) 2003-01-23
ZA974029B (en) 1998-02-19
AU727899B2 (en) 2001-01-04
AU2938597A (en) 1997-12-05
PA8429801A1 (es) 2000-05-24
AR007100A1 (es) 1999-10-13
CN1124255C (zh) 2003-10-15
EP0907632B1 (en) 2002-12-11

Similar Documents

Publication Publication Date Title
UY27167A1 (es) Inhibidores de piridina de metaloproteinasas de la matriz
SV1997000036A (es) Inhibisores de matrices metaloproteasas mediante acidos biaril oxobutiricos sustituidos
BR9713186A (pt) Inibidores de metaloprotease 1,3-diheterocìclicos
BRPI0407919A (pt) pirrolopirimidinas espiro-substituìdas
BR9714155A (pt) Prevenção da perda e reposição da massa óssea por certos agonistas de prostaglandina.
SV1997000037A (es) Inhibisor de matrices de metaloproteasas mediante compuestos sustituidos de fenalquilo,
BR9813028A (pt) Agonistas de prostaglandina e seu uso para tratar distúrbios nos ossos
ES2179451T3 (es) Compuestos de 2-alquiliden-19-nor-vitamina d.
BR0009869A (pt) Método para inibir a produção e/ou secreção de citoquina, e, composição farmacêutica
NO20000784L (no) Nye aggrecanaseinhibitorer og matriksmetalloproteinaser for behandling av artritt
ES2092958B1 (es) Procedimiento para la sintesis de tensioactivos cationicos derivados de la condensacion de acidos grasos con aminoacidos de caracter basico esterificados y su aplicacion como agentes antimicrobianos.
BRPI9701248B1 (pt) Compostos para a terapia de tumores e distúrbios inflamatórios, produto farmacêutico e formulação farmacêutica dos mesmos
FI961976A0 (fi) Peptidyyliyhdisteitä ja niiden terapeuttinen käyttö metalloproteinaasien inhibiittoreina
DK0988292T3 (da) Piperazinderivater og deres anvendelse som antiinflammationsmidler
AR013001A1 (es) Derivados de la piperazina, procedimientos para prepararlos, las composiciones farmaceuticas que los contienen, su utilizacion como medicamentoy el metodo para tratar enfermedades mediadas por la taquinina.
ES2132678T3 (es) Sal de nimesulido hidrosoluble y su utilizacion para el tratamiento de las afecciones inflamatorias.
ES2136037B1 (es) Inhibidores de sulfamida-metaloproteasa
HN1997000067A (es) Acidos oxibutiricos sustituidos como inhibidores de la metaloproteasa de matriz
BR9713178A (pt) Inbidores espirocìclicos da metaloprotease.
CO2024006269A2 (es) Inhibidores de molécula pequeña de proteasa 1 específica de ubiquitina (usp1) y usos de los mismos
MX9307608A (es) Inhibidores de la liberacion de la citocina y antagonistas de la il-1,procedimiento para su preparacion y composiciones farmaceuticas que loscontienen.
ECSP003707A (es) Diazepanes
Choi et al. Potential therapeutic application of small molecule with sulfonamide for chondrogenic differentiation and articular cartilage repair
ID28365A (id) Turunan produk alami yang baru
PA8429301A1 (es) Biarilacetilenos como inhibidores de la metaloproteasa de matriz.

Legal Events

Date Code Title Description
FD Lapse